ABL Bio to Present 4-1BB-Based Bispecific Antibody Platform at PEGS Boston Summit

ABL Bio, a company specializing in bispecific antibodies, announced on the 6th that it will participate in the PEGS Summit, to be held in Boston, USA from May 11 to 15 (local time), where it will introduce its 4-1BB-based bispecific antibody platform, Grabody-T.

원본보기 아이콘

The PEGS Boston Summit is an international event focusing on biopharmaceuticals and protein engineering, where pharmaceutical and biotechnology company representatives share innovative technologies, new drug development strategies, and success stories.

On May 11, ABL Bio CEO Sang Hoon Lee will give an oral presentation on "Clinical Efficacy and Safety Profile of Next-Generation 4-1BB T Cell Engaging Bispecific Antibody Grabody-T."

Through this presentation, ABL Bio plans to introduce the clinical anti-cancer efficacy and safety of its Grabody-T-based bispecific antibodies ABL111 (Zivastomig) and ABL503 (Lazistomig), and to seek business opportunities.

ABL111 is a bispecific antibody that simultaneously targets Claudin18.2 and 4-1BB. It is currently in a Phase 2 clinical trial for metastatic gastric cancer patients in combination with the PD-1 inhibitor Nivolumab and chemotherapy. ABL503, a bispecific antibody targeting PD-L1 and 4-1BB, is preparing to expand its clinical development into combination therapies based on Phase 1 monotherapy data.

Sang Hoon Lee, CEO of ABL Bio, stated, "4-1BB-based bispecific antibodies are attracting increasing global attention as they have demonstrated strong anti-cancer efficacy in clinical trials while overcoming the liver toxicity limitations previously seen with 4-1BB monoclonal antibodies. Among our Grabody-T-based bispecific antibodies, ABL111, which is progressing the fastest in development, has been in Phase 2 clinical trials since February, and we aim to initiate patient enrollment for Phase 3 clinical trials in the fourth quarter of this year."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.